Search Weight Loss Topics:

Home » Long Term Weight Loss » Libtayo (cemiplimab-rwlc) Longer-term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ASCO 2020 Show Durable Responses that Deepen…

TARRYTOWN, N.Y. and PARIS, May 29, 2020 /PRNewswire/ --

Across all groups combined, complete responses (CR) are now 16%; in the metastatic group with the longest follow-up CRs are 20%, nearly tripling with two additional years of follow-up

Regeneron Pharmaceuticals, Inc.. (NASDAQ: REGN) and Sanofi today announced new, longer-term data for PD-1 inhibitor Libtayo (cemiplimab-rwlc) from a pivotal Phase 2 trial in advanced cutaneous squamous cell carcinoma (CSCC), the deadliest non-melanoma skin cancer. These results demonstrate both longer durability and higher complete response (CR) rates than previously reported. Furthermore, the data make up part of the largest and most mature prospective clinical dataset in patients with metastatic CSCC (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or radiation. The data were presented during the virtual 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.

"The three-year follow-up data demonstrate significant long-term outcomes with Libtayo, which is now standard-of-care for patients with advanced CSCC in many countries," said Dr. Danny Rischin, Director, Department of Medical Oncology at Peter MacCallum Cancer Centre, Victoria, Australia. "The Libtayo data on duration of response and overall survival provide new insights into the longer-term treatment of advanced CSCC, with the median still not reached for either measure. Remarkably, it is exciting to see the number of complete responses increase with longer follow-up, which reinforces the potential ongoing benefit of Libtayo treatment in this aggressive skin cancer."

With up to three years of follow-up, results from the pivotal Phase 2 trial showed 46% of patients (95% CI: 39%-53%) experienced substantial tumor shrinkage following Libtayo treatment, with a median time to response of 2 months (interquartilerange: 2-4 months). Furthermore, more patients (16%) saw their tumors disappear completely over time compared to previous analyses. Among patients with metastatic disease who had the longest available follow-up (Group 1 in table below), 20% of patients have now achieved a CR, increasing from 7% in the 2017 primary analysis. Among patients who achieved a CR in any group, median time to CR was 11 months (interquartilerange: 7-15 months). Median overall survival and median duration of response have yet to be reached for any treatment group.

Results by treatment group were as follows:

Group 1:

mCSCC

3 mg/kg every

2 weeks

(n=59)

Group 2:

laCSCC

3 mg/kg every2 weeks

(n=78)

Group 3:

mCSCC

350 mg every

3 weeks

(n=56)

Total

(n=193)

Median duration of follow-up (range)

19 months

(136)

16 months

(136)

17 months

(126)

16 months

(136)

Objective response rate (95% confidence interval [CI])

51%

(38%64%)

45%

(34%57%)

43%

(30%57%)

46%

(39%53%)

CR (n)

20%

(12)

13%

(10)

16%

(9)

16%

(31)

Partial response (n)

31%

(18)

32%

(25)

27%

(15)

30%

(58)

Median observed time to response (interquartile range)*

2 months

(22)

2 months

(24)

2 months

(24)

2 months

(24)

Median observed time to CR (interquartile range)

11 months

(718)

10 months

(713)

12 months

(817)

11 months

(715)

Median duration of response (95% CI)*

Not reached

(21, NE)

Not reached

(18, NE)

Not reached

(NE, NE)

Not reached

(29, NE)

Median overall survival

Not reached

Not reached

Not reached

Not reached

NE = not evaluable

*Based on number of patients with confirmed complete or partial response and Kaplan-Meier estimation.

CR rates over time were as follows:

Group 1:

mCSCC

3 mg/kg every

Go here to read the rest:
Libtayo (cemiplimab-rwlc) Longer-term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ASCO 2020 Show Durable Responses that Deepen...

Your Full Name
Your Email
Your Phone Number
Select your age (30+ only)	30313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120
Select Your US State	Select Your StateAlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWashington,DCWest VirginiaWisconsinWyoming
Program Choice	Select Your ProgramInjectable HGHInjectable TestoteroneInjectable SermorelinInjectable Weight LossInjectable HCG DietInjectable Vitamins
Confirm over 30 years old	Yes
Confirm that you resident in USA	Yes
This is a Serious Inquiry	Yes
Message:

Home » Long Term Weight Loss » Libtayo (cemiplimab-rwlc) Longer-term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ASCO 2020 Show Durable Responses that Deepen…